FDA Approvals in RCC and CML, Priority Review Designations in NSCLC and RCC, and More

The European Union’s Committee for Medicinal Products for Human Use (CHMP) recommends the approval of Herzuma, a trastuzumab biosimilar, for treating HER2-positive gastric cancer patients. The CHMP’s opinion now goes to the full European Commission for final review.